SCHEMBL10134341

SCHEMBL10134341

CC(C)N1CCN(C(=O)c2ccc(Nc3ccc(-c4ccc5c(c4)CNC5=O)n4ccnc34)cc2F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 3/20 0.44
MTOR P42345 3/20 0.37
PTK6 Q13882 2/20 0.37
AURKB Q96GD4 1/20 0.37
TNF P01375 1/20 0.36
GSK3B P49841 2/20 0.35
SYK P43405 2/20 0.35
F9 P00740 1/20 0.34
CDK6 Q00534 4/20 0.34
CDK4 P11802 3/20 0.34
CCND1 P24385 2/20 0.34
PIK3CA P42336 1/20 0.34
CCND3 P30281 1/20 0.34
DAPK3 O43293 1/20 0.34
NTRK1 P04629 1/20 0.34
PIM1 P11309 1/20 0.34
FLT3 P36888 1/20 0.34
ROCK1 Q13464 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
CSF1R P07333 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14162585 0.93 MAPKAPK5 (0.44) MAPKAPK5MTORPTK6AURKBTNF
SCHEMBL13922250 0.92 MAPKAPK5 (0.44) MAPKAPK5PTK6TNFGSK3BSYK
SCHEMBL1685115 0.89 MAPKAPK5 (0.48) MAPKAPK5GSK3BSYKCDK6CDK4
SCHEMBL1685139 0.87 MAPKAPK5 (0.48) MAPKAPK5GSK3BSYKF9CDK6
SCHEMBL12618951 0.86 MAPKAPK5 (0.47) MAPKAPK5MTORTNFGSK3BSYK
SCHEMBL10134096 0.86 MAPKAPK5 (0.48) MAPKAPK5MTORTNFGSK3BSYK
SCHEMBL10166168 0.85 PTK6 (0.38) MAPKAPK5MTORPTK6AURKBSYK
SCHEMBL14162768 0.85 MAPKAPK5 (0.46) MAPKAPK5TNFGSK3BSYKF9
SCHEMBL1685248 0.85 MAPKAPK5 (0.42) MAPKAPK5MTORGSK3BCDK6CDK4
SCHEMBL1685138 0.83 MAPKAPK5 (0.61) MAPKAPK5SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885MTOR 1365/4885PTK6 1098/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885MTOR 1365/4885PTK6 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.